NeOnc Technologies appoints Nasim Shomali to its Board, enhancing expertise in strategy and financial planning for CNS cancer therapies.
Quiver AI Summary
NeOnc Technologies Holdings, Inc., a biopharmaceutical company focused on developing therapies for central nervous system cancers, has appointed Nasim Shomali to its Board of Directors, effective July 1, 2026. The company's Executive Chairman, Amir Heshmatpour, expressed enthusiasm over her appointment, noting her significant scientific, strategic, and financial expertise which will be valuable as NeOnc approaches key clinical milestones and expands internationally. Shomali, who has over a decade of experience in corporate strategy and financial planning, emphasized the company’s innovative approaches in treating challenging CNS cancers. Her background includes a role as a Strategy Executive at Accenture and experience in private equity. NeOnc is currently advancing its NEO100 and NEO212 therapeutics in Phase II clinical trials.
Potential Positives
- The appointment of Nasim Shomali to the Board of Directors brings significant scientific and financial expertise, which can enhance the company's strategic direction and capital allocation.
- NeOnc's proprietary drug candidates NEO100 and NEO212 are advancing in Phase II clinical trials, indicating progress in their development and potential for commercialization.
- The company possesses a robust patent portfolio that extends to 2038, which provides a competitive edge and potential for long-term value creation in CNS therapeutics.
Potential Negatives
- Appointment of a new board member may indicate a potential lack of stability or confidence in the current leadership structure, raising concerns about governance.
- Reference to significant clinical and regulatory milestones suggests potential high stakes and pressures on the company's performance, which may create uncertainty for investors.
- Forward-looking statements include cautionary notes about the unpredictability of clinical trial outcomes, highlighting risk factors that could adversely affect the company's future success.
FAQ
What is the significance of Nasim Shomali’s appointment to NeOnc's Board?
Nasim Shomali brings valuable expertise in science, strategy, and finance, enhancing NeOnc’s capabilities at a crucial development stage.
What experience does Nasim Shomali have in the biopharmaceutical industry?
Ms. Shomali has over a decade of experience advising large organizations on strategy and financial planning, particularly in life sciences.
What are NeOnc's NEO100 and NEO212 therapeutics?
NEO100 and NEO212 are novel chemotherapy agents currently in Phase II clinical trials, aimed at treating CNS cancers.
How does NeOnc approach the blood-brain barrier challenge?
NeOnc utilizes its NEO™ drug development platform to create therapeutics designed to effectively overcome the blood-brain barrier.
Where can I find more information about NeOnc's initiatives?
More information about NeOnc Technologies and its innovative therapies can be found on their official website at https://neonc.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NTHI Insider Trading Activity
$NTHI insiders have traded $NTHI stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NTHI stock by insiders over the last 6 months:
- AMIR F HESHMATPOUR (President) has made 8 purchases buying 80,000 shares for an estimated $420,120 and 0 sales.
- YOUSHA NEMAN-EBRAHIM (Chief Clinical Officer) purchased 500 shares for an estimated $2,440
- DAVID JR. SUH, (Chief Accounting Officer) purchased 200 shares for an estimated $1,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NTHI Hedge Fund Activity
We have seen 13 institutional investors add shares of $NTHI stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CINCTIVE CAPITAL MANAGEMENT LP added 1,425,526 shares (+inf%) to their portfolio in Q1 2026, for an estimated $9,992,937
- HIGHPOINT ADVISOR GROUP LLC removed 1,144,640 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $8,023,926
- WESTMOUNT PARTNERS, LLC added 153,858 shares (+355.2%) to their portfolio in Q2 2026, for an estimated $696,976
- HUDSON BAY CAPITAL MANAGEMENT LP added 147,360 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,032,993
- MILLENNIUM MANAGEMENT LLC added 119,249 shares (+inf%) to their portfolio in Q1 2026, for an estimated $835,935
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 91,036 shares (+inf%) to their portfolio in Q1 2026, for an estimated $638,162
- MORGAN STANLEY added 43,718 shares (+532.9%) to their portfolio in Q1 2026, for an estimated $306,463
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$NTHI Price Targets
Multiple analysts have issued price targets for $NTHI recently. We have seen 3 analysts offer price targets for $NTHI in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Thomas Shrader from BTIG set a target price of $15.0 on 05/26/2026
- Matthew Venezia from Alliance Global Partners set a target price of $13.0 on 05/19/2026
- Jason McCarthy from Maxim Group set a target price of $20.0 on 05/18/2026
Full Release
CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced the appointment of Nasim Shomali to its Board of Directors, effective July 1, 2026.
"We are delighted to welcome Nasim to our Board at an important time for NeOnc," said Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. "Nasim brings a valuable combination of scientific, strategic and financial expertise. She has advised some of the world’s largest and most complex organizations on strategy, financial planning and long-term value creation, while her scientific background enables her to engage meaningfully with our clinical programs. As we approach important clinical and regulatory milestones and expand our development efforts internationally, Nasim’s judgment and disciplined approach to capital allocation will strengthen our Board and support our mission to build lasting value for patients and shareholders."
Ms. Shomali commented, "My career has been built at the intersection of the laboratory and the capital markets, and that is the perspective I hope to bring to the NeOnc Board. The Company is pursuing genuinely novel approaches to reach cancers of the brain and central nervous system that remain among the hardest to treat, and it is doing so with a rigor that shows in both the science and the way the business is being built." She continued, "I am honored to join a Board and management team of this caliber, and I look forward to supporting the team as NeOnc advances its clinical programs and brings these therapies closer to the patients who need them."
Ms. Shomali brings more than a decade of experience advising large, complex organizations on corporate strategy, operating models, financial planning, and organizational transformation, grounded in formal training in biomedical engineering and finance. Most recently, she served as a Strategy Executive at Accenture, where she advised Fortune-100 and multinational enterprises across the life sciences, technology, and energy sectors. Her work spanned corporate strategy development, financial and pro-forma modeling, market sizing, operating-model design, and C-suite and Board-level advisory, including engagements in the medical technology sector focused on product lifecycle economics and next-generation product design.
Earlier in her career, Ms. Shomali gained private equity experience at Maybrook Capital Partners, where she led commercial and financial diligence and developed investment-grade analyses, and she began her career in an engineering role at InBios International, Inc., a life sciences company, where she worked on manufacturing throughput and product profitability initiatives.
Ms. Shomali holds a Master of Business Administration in Finance from the UCLA Anderson School of Management and completed an executive program in sustainable leadership development at the Yale School of Management. She earned a Bachelor of Science in Bioengineering and a Bachelor of Arts in Mathematics from the University of Washington.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit https://neonc.com
Important Cautions Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as "may," "will," "should," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "predict," "potential," "continue," "evaluating," or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Please refer to the "Risk Factors" section of our quarterly and annual reports on Form 10-Q and Form 10-K as filed with the Securities and Exchange Commission, along with other cautionary language in those reports and risk factors and other cautionary language in our subsequent filings with the Securities and Exchange Commission, which outline important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the fact that results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials, announced or published data from our clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data, and our product candidates are in preclinical and clinical stages of development, are not approved for commercial sale and might never receive regulatory approval or become commercially viable.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
"NEO100" and "NEO212" are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
[email protected]
Investor Contact:
Jon Nugent
Jon Nugent Communications
[email protected]
205-566-3026
This press release was published by a CLEAR® Verified individual.
